H2AX and gastrointestinal stromal tumor: As shown in an earlier study by our group, the prototype proteasome inhibitor bortezomib has a dual mechanism of action in GIST through upregulation of the pro-apoptotic histone H2AX and inhibition of transcription resulting in loss of KIT expression6.